New interactive forum for clinicians discussing difficult CML cases

To share and enhance best practice management of CML the iCMLf has opened a discussion forum where experts and interested clinicians can discuss difficult, or interesting CML patient cases. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) to the iCMLf web-site coordinator, Jan Geissler. Each case accepted will be published in the discussion forum with a brief response. Further comments, questions and discussion are invited.

Read more

Remembering John Goldman

It is with great sorrow that the iCMLf has learned of the death of Professor John Goldman, after a short illness. 

With a worldwide reputation in the study of the biology and treatment of CML John was a true leader, teacher and inspiration to so many. He constantly sought to share his knowledge and experience for the improvement of the treatment of CML globally. So many people with CML are with us now and have benefited from his tireless efforts.

Read more

Professor of Medicine Chair, Department of Haematology Hammersmith Hospital
Imperial College, London (UK)

Professor Jane Apperley is the Chair of the Department of Haematology at the Imperial College and the Chief of Service for Clinical Haematology at the Imperial College Healthcare NHS Trust in London, England. Jane Apperley served as the President of both the European Group of Blood and Marrow Transplantation and the British Society of Blood and Marrow Transplantation. She also serves on the Advisory Board of the Centre for International Blood and Marrow Transplant Research.

She qualified in Medicine from the University of Birmingham and after initial specialization in internal medicine she completed specialist training in hematology in Birmingham, London, Cambridge and Boston.

Her particular interests are the biology and management of CML, which has led to an extensive experience in stem cell transplantation and to the use of signal transduction inhibitors. Her group at the Hammersmith Hospital site has extensive experience in the use of the first- and second-generation TKI’s, particularly in the areas of molecular monitoring and mechanisms of drug resistance. She has a long-standing interest in the ways in which hematologic diseases and their treatment impact fertility, pregnancy, and fetal outcome.

Leader, Myeloproliferative Neoplasms (MPN) Program

Memorial Sloan-Kettering Cancer Center, New York

Professor Michael Mauro directs the Myeloproliferative Neoplasms (MPN) Program at the Memorial Sloan-Kettering Cancer Center in New York. He received his medical degree from Dartmouth Medical School and completed his residency and fellowship training at New York-Presbyterian Hospital/Weill Cornell Medical Center. For more than a decade he worked with Dr Brian Druker at the OHSU Knight Cancer Institute in Portland, Oregon with a focus on research in CML. There he directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML. His clinical focus is in CML with interest in therapy optimization, novel therapies, treatment free remission and pregnancy/fertility, as well as other myeloproliferative neoplasms, including myelofibrosis, polycythemia and thrombocytosis and less common conditions such as eosinophillic and mast cell disorders.